US · Healthcare · Biotechnology
EPS came in at -0.90 against a street estimate of -0.81 — a miss of 11.1%.
Analysts rate Vor Biopharma Inc a strong buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $39.00.
| Fund | Stake |
|---|---|
| TCG Crossover Management, LLC | 9.59% |
| FMR Inc | 8.34% |
| FCPM III SERVICES BV | 6.96% |
| BlackRock Inc | 5.86% |
| VR Adviser, LLC | 5.14% |
| State Street Corp | 4.42% |
| Frazier Life Sciences Management, L.P. | 4.30% |
| RA Capital Management, LLC | 4.06% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Vor Biopharma is a clinical-stage biotechnology company developing telitacicept, a dual-target protein intended to reduce autoreac | 2026-10-30 |
| Quarterly report · Q2 2026 VOR BIOPHARMA INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Liquidity: $107.9 million in cash and $358.3 million in marketable securities as | 2026-08-11 |
| Board / officer change · Q3 2026 VOR BIOPHARMA INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Vor Biopharma Inc. (Nasdaq: VOR) • Filing Date: July 7, 2026 • Report covers events fro | 2026-07-07 |
| Shareholder vote results · Q2 2026 VOR BIOPHARMA INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 11, 2026 with 34,012,004 shares present or represented (62.77% of votin | 2026-06-12 |
| Reg FD disclosure · Q2 2026 VOR BIOPHARMA INC. – 8-K SUMMARY HEADLINE NUMBERS • Company: Vor Biopharma Inc. (ticker: VOR, Nasdaq Global Select Market) • Report Date: June 8, 20 | 2026-06-08 |
| Quarterly report · Q1 2026 VOR BIOPHARMA INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $169.9 million in cash and cash equivalents plus $321.7 million in marke | 2026-05-13 |
| Proxy statement · Q2 2026 VOR BIOPHARMA INC. – 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two Class II director nominees (three-yea | 2026-04-27 |
| Annual report FY2025 VOR BIOPHARMA INC. — ANNUAL REPORT SUMMARY (FISCAL YEAR ENDED DECEMBER 31, 2025) HEADLINE NUMBERS • Market capitalization as of June 30, 2025: appro | 2026-03-30 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 1 : 20 effective Sep 19, 2025 | 2025-09-19 |
| Announcement | Date |
|---|---|
| Telitacicept receives NMPA conditional approval for IgA nephropathy treatment in China Vor Bio announced that its partner RemeGen received conditional approval from China's National Medicinal Products Administration (NMPA) for telitacicept to treat IgA nephropathy (IgAN), a se | 2026-06-08 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vor Biopharma Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.